Data gathered: December 7
AI Stock Analysis - Allogene Therapeutics (ALLO)
Analysis generated April 22, 2024. Powered by Chat GPT.
Allogene Therapeutics is a clinical-stage biotechnology company that focuses on the development and commercialization of allogeneic chimeric antigen receptor T-cell (CAR T) therapies for cancer. Allogene’s technology involves genetically engineering T cells to target and destroy cancer cells. Unlike traditional autologous CAR T therapies that are personalized for each patient, Allogene’s allogeneic approach uses T cells derived from healthy donors, which can be mass-produced and offer a potential for off-the-shelf treatments. The company’s pioneering approach in the CAR T space has the potential to transform cancer treatment.
Stock Alerts - Allogene Therapeutics (ALLO)
 |
Allogene Therapeutics | December 6 Price is up by 5.4% in the last 24h. |
|
Allogene Therapeutics | December 5 Price is down by -5.5% in the last 24h. |
|
Allogene Therapeutics | December 3 Price is down by -5.9% in the last 24h. |
|
Allogene Therapeutics | November 26 Price is up by 11.6% in the last 24h. |
Alternative Data for Allogene Therapeutics
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 11,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 20 | Sign up | Sign up | Sign up |
| Patents | 33 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,931 | Sign up | Sign up | Sign up |
| Twitter Followers | 2,424 | Sign up | Sign up | Sign up |
| Twitter Mentions | 26 | Sign up | Sign up | Sign up |
| News Mentions | 1 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 63 | Sign up | Sign up | Sign up |
| Linkedin Employees | 284 | Sign up | Sign up | Sign up |
About Allogene Therapeutics
Allogene Therapeutics is a clinical stage biotechnology company leading the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer.
| Price | $2.19 |
| Target Price | Sign up |
| Volume | 2,640,000 |
| Market Cap | $449M |
| Year Range | $2.05 - $4.47 |
| Dividend Yield | 0% |
| Analyst Rating | 80% buy |
| Industry | Biotechnology |
In the news
 |
Fmr LLC Decreases Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)December 6 - ETF Daily News |
|
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Sees Large Decline in Short InterestDecember 4 - ETF Daily News |
 |
Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock?December 2 - Yahoo |
 |
Allogene Therapeutics (ALLO) Upgraded to Buy: Here's WhyNovember 25 - Yahoo |
Allogene Therapeutics Announces Participation in December Investor ConferencesNovember 19 - GlobeNewswire |
|
Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) ConvergenceNovember 18 - GlobeNewswire |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 27M | -27M | -66M | -72M | -0.320 |
| Q2 '24 | 0 | 21M | -21M | -66M | -63M | -0.350 |
| Q1 '24 | 22,000 | 17M | -17M | -65M | -66M | -0.380 |
| Q4 '23 | 23M | 37M | -15M | -86M | -68M | -0.430 |
| Q3 '23 | 43,000 | 17M | -17M | -62M | -59M | -0.370 |
Insider Transactions View All
| MESSEMER DEBORAH M. filed to sell 166,765 shares at $2.3. June 20 '24 |
| Humer Franz B filed to sell 255,253 shares at $2.3. June 3 '24 |
| Belldegrun Arie filed to buy 1,724,137 shares at $2.9. May 20 '24 |
| Parker Geoffrey M. filed to buy 819,590 shares at $3.6. March 6 '24 |
| MESSEMER DEBORAH M. filed to sell 62,456 shares at $2.7. December 20 '23 |
Similar companies
Read more about Allogene Therapeutics (ALLO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Allogene Therapeutics?
The Market Cap of Allogene Therapeutics is $449M.
What is the current stock price of Allogene Therapeutics?
Currently, the price of one share of Allogene Therapeutics stock is $2.19.
How can I analyze the ALLO stock price chart for investment decisions?
The ALLO stock price chart above provides a comprehensive visual representation of Allogene Therapeutics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Allogene Therapeutics shares. Our platform offers an up-to-date ALLO stock price chart, along with technical data analysis and alternative data insights.
Does ALLO offer dividends to its shareholders?
As of our latest update, Allogene Therapeutics (ALLO) does not offer dividends to its shareholders. Investors interested in Allogene Therapeutics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Allogene Therapeutics?
Some of the similar stocks of Allogene Therapeutics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.